;PMID: 789067
;source_file_1938.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..127] = [t:49..127]
;2)section:[e:131..143] = [t:131..143]
;3)sentence:[e:147..385] = [t:147..385]
;4)sentence:[e:387..446] = [t:387..446]
;5)sentence:[e:447..703] = [t:447..703]
;6)sentence:[e:705..852] = [t:705..852]
;7)sentence:[e:853..943] = [t:853..943]
;8)sentence:[e:945..1006] = [t:945..1006]
;9)sentence:[e:1007..1211] = [t:1007..1211]
;10)section:[e:1215..1233] = [t:1215..1233]
;11)section:[e:1239..1245] = [t:1239..1245]
;12)section:[e:1249..1292] = [t:1249..1292]

;section 0 Span:0..43
;Environ Health Perspect. 1976 Apr;14:29-37.
(SEC
  (FRAG (NNP:[0..7] Environ) (NNP:[8..14] Health) (NNP:[15..23] Perspect)
        (.:[23..24] .) (CD:[25..29] 1976) (CC:[30..36] Apr;14)
        (CD:[36..40] :29-) (CD:[40..42] 37) (.:[42..43] .)))

;sentence 1 Span:49..127
;Methylenedioxyphenyl insecticide synergists as potential human health
;hazards.
;[49..81]:substance:"Methylenedioxyphenyl insecticide"
;[82..92]:substance:"synergists"
(SENT
  (NP-HLN
    (NP
       (NN:[49..69] Methylenedioxyphenyl) (NN:[70..81] insecticide)
      (NNS:[82..92] synergists))
    (PP (IN:[93..95] as)
      (NP (JJ:[96..105] potential) (JJ:[106..111] human) (NN:[112..118] health)
          (NNS:[119..126] hazards)))
    (.:[126..127] .)))

;section 2 Span:131..143
;Franklin MR.
(SEC
  (FRAG (NNP:[131..139] Franklin) (NNP:[140..143] MR.)))

;sentence 3 Span:147..385
;The effects of methylenedioxyphenyl insecticide synergists on human health 
;arise, not from their intrinsic toxicity which is relatively low, but from
;their  dual effect on the oxidative detoxication or intoxication processes of
;the body.
;[162..194]:substance:"methylenedioxyphenyl insecticide"
;[195..205]:substance:"synergists"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[147..150] The) (NNS:[151..158] effects))
      (PP (IN:[159..161] of)
        (NP
           (NN:[162..182] methylenedioxyphenyl) (NN:[183..194] insecticide)
          (NNS:[195..205] synergists)))
      (PP (IN:[206..208] on)
        (NP (JJ:[209..214] human) (NN:[215..221] health))))
    (VP (VBP:[223..228] arise) (,:[228..229] ,)
      (PP (RB:[230..233] not)
        (PP (IN:[234..238] from)
          (NP
            (NP (PRP$:[239..244] their) (JJ:[245..254] intrinsic)
                (NN:[255..263] toxicity))
            (SBAR
              (WHNP-2 (WDT:[264..269] which))
              (S
                (NP-SBJ-2 (-NONE-:[269..269] *T*))
                (VP (VBZ:[270..272] is)
                  (ADJP-PRD (RB:[273..283] relatively) (JJ:[284..287] low)))))))
        (,:[287..288] ,) (CC:[289..292] but)
        (PP (IN:[293..297] from)
          (NP
            (NP (PRP$:[298..303] their) (JJ:[305..309] dual)
                (NN:[310..316] effect))
            (PP (IN:[317..319] on)
              (NP
                (NP (DT:[320..323] the)
                  (NML
                    (NML
                      (ADJP-3 (JJ:[324..333] oxidative))
                      (NN:[334..346] detoxication)
                      (NML-1 (-NONE-:[346..346] *P*)))
                    (CC:[347..349] or)
                    (NML
                      (ADJP-3 (-NONE-:[349..349] *P*))
                      (NN:[350..362] intoxication)
                      (NML-1 (NNS:[363..372] processes)))))
                (PP (IN:[373..375] of)
                  (NP (DT:[376..379] the) (NN:[380..384] body)))))))))
    (.:[384..385] .)))

;sentence 4 Span:387..446
;They are able to inhibit these reactions by two mechanisms.
(SENT
  (S
    (NP-SBJ (PRP:[387..391] They))
    (VP (VBP:[392..395] are)
      (ADJP-PRD (JJ:[396..400] able)
        (S
          (NP-SBJ (-NONE-:[400..400] *))
          (VP (TO:[401..403] to)
            (VP (VB:[404..411] inhibit)
              (NP (DT:[412..417] these) (NNS:[418..427] reactions))
              (PP-MNR (IN:[428..430] by)
                (NP (CD:[431..434] two) (NNS:[435..445] mechanisms))))))))
    (.:[445..446] .)))

;sentence 5 Span:447..703
;They are substrates  for mixed function oxidation and, thus, compete with
;other xenobiotics for  available enzyme, and an intermediate in their
;metabolism is able to bind with  cytochrome P-450 to form an inactive complex
;which absorbs maximally at 455 nm.
;[456..466]:substance:"substrates"
;[527..538]:substance:"xenobiotics"
;[554..560]:substance:"enzyme"
;[569..581]:substance:"intermediate"
;[624..640]:cyp450:"cytochrome P-450"
;[661..668]:substance:"complex"
;[696..699]:quantitative-value:"455"
;[700..702]:quantitative-units:"nm"
(SENT
  (S
    (S
      (NP-SBJ (PRP:[447..451] They))
      (VP
        (VP (VBP:[452..455] are)
          (NP-PRD
            (NP (NNS:[456..466] substrates))
            (PP (IN:[468..471] for)
              (NP
                (NML (VBN:[472..477] mixed) (NN:[478..486] function))
                (NN:[487..496] oxidation)))))
        (CC:[497..500] and) (,:[500..501] ,)
        (VP
          (ADVP (RB:[502..506] thus))
          (,:[506..507] ,) (VBP:[508..515] compete)
          (PP (IN:[516..520] with)
            (NP (JJ:[521..526] other) (NNS:[527..538] xenobiotics)))
          (PP (IN:[539..542] for)
            (NP (JJ:[544..553] available) (NN:[554..560] enzyme))))))
    (,:[560..561] ,) (CC:[562..565] and)
    (S
      (NP-SBJ
        (NP (DT:[566..568] an) (NN:[569..581] intermediate))
        (PP (IN:[582..584] in)
          (NP (PRP$:[585..590] their) (NN:[591..601] metabolism))))
      (VP (VBZ:[602..604] is)
        (ADJP-PRD (JJ:[605..609] able)
          (S
            (NP-SBJ (-NONE-:[609..609] *))
            (VP (TO:[610..612] to)
              (VP (VB:[613..617] bind)
                (PP-CLR (IN:[618..622] with)
                  (NP (NN:[624..634] cytochrome) (NN:[635..640] P-450)))
                (S-PRP
                  (NP-SBJ (-NONE-:[640..640] *))
                  (VP (TO:[641..643] to)
                    (VP (VB:[644..648] form)
                      (NP
                        (NP (DT:[649..651] an) (JJ:[652..660] inactive)
                            (NN:[661..668] complex))
                        (SBAR
                          (WHNP-1 (WDT:[669..674] which))
                          (S
                            (NP-SBJ-1 (-NONE-:[674..674] *T*))
                            (VP (VBZ:[675..682] absorbs)
                              (ADVP (RB:[683..692] maximally))
                              (PP (IN:[693..695] at)
                                (NP (CD:[696..699] 455) (NN:[700..702] nm))))))))))))))))
    (.:[702..703] .)))

;sentence 6 Span:705..852
;In addition, they are able to activate xenobiotic metabolism by induction
;(the  increased synthesis and retention) of microsomal oxidative enzymes.
;[744..754]:substance:"xenobiotic"
;[844..851]:substance:"enzymes"
(SENT
  (S
    (PP (IN:[705..707] In)
      (NP (NN:[708..716] addition)))
    (,:[716..717] ,)
    (NP-SBJ (PRP:[718..722] they))
    (VP (VBP:[723..726] are)
      (ADJP-PRD (JJ:[727..731] able)
        (S
          (NP-SBJ (-NONE-:[731..731] *))
          (VP (TO:[732..734] to)
            (VP (VB:[735..743] activate)
              (NP (JJ:[744..754] xenobiotic) (NN:[755..765] metabolism))
              (PP-MNR (IN:[766..768] by)
                (NP
                  (NP
                    (NP (NN:[769..778] induction))
                    (PRN (-LRB-:[779..780] -LRB-)
                      (NP (DT:[780..783] the)
                        (NML
                          (NML
                            (ADJP-1 (VBN:[785..794] increased))
                            (NN:[795..804] synthesis))
                          (CC:[805..808] and)
                          (NML
                            (ADJP-1 (-NONE-:[808..808] *P*))
                            (NN:[809..818] retention))))
                      (-RRB-:[818..819] -RRB-)))
                  (PP (IN:[820..822] of)
                    (NP (JJ:[823..833] microsomal) (JJ:[834..843] oxidative)
                        (NNS:[844..851] enzymes))))))))))
    (.:[851..852] .)))

;sentence 7 Span:853..943
;Evidence for  these effects is presented, including spectroscopic and enzyme
;kinetic data.
;[923..929]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[853..861] Evidence))
      (PP (IN:[862..865] for)
        (NP (DT:[867..872] these) (NNS:[873..880] effects))))
    (VP (VBZ:[881..883] is)
      (VP (VBN:[884..893] presented)
        (NP-2 (-NONE-:[893..893] *))
        (,:[893..894] ,)
        (PP (VBG:[895..904] including)
          (NP
            (NP (JJ:[905..918] spectroscopic)
              (NML-1 (-NONE-:[918..918] *P*)))
            (CC:[919..922] and)
            (NP (NN:[923..929] enzyme) (JJ:[930..937] kinetic)
              (NML-1 (NN:[938..942] data)))))))
    (.:[942..943] .)))

;sentence 8 Span:945..1006
;Correlations with existing in vivo observations are outlined.
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[945..957] Correlations))
      (PP (IN:[958..962] with)
        (NP (VBG:[963..971] existing)
          (ADJP (FW:[972..974] in) (FW:[975..979] vivo))
          (NNS:[980..992] observations))))
    (VP (VBP:[993..996] are)
      (VP (VBN:[997..1005] outlined)
        (NP-1 (-NONE-:[1005..1005] *))))
    (.:[1005..1006] .)))

;sentence 9 Span:1007..1211
;The inhibition and  induction of cytochrome P-450, the central enzyme in the
;metabolism of  xenobiotics, thus provides the focus for consideration of
;methylenedioxyphenyl  synergists as potential hazards.
;[1040..1056]:cyp450:"cytochrome P-450"
;[1070..1076]:cyp450:"enzyme"
;[1099..1110]:substance:"xenobiotics"
;[1157..1177]:substance:"methylenedioxyphenyl"
;[1179..1189]:substance:"synergists"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1007..1010] The) (NN:[1011..1021] inhibition)
          (CC:[1022..1025] and) (NN:[1027..1036] induction))
      (PP (IN:[1037..1039] of)
        (NP
          (NP (NN:[1040..1050] cytochrome) (NN:[1051..1056] P-450))
          (,:[1056..1057] ,)
          (NP
            (NP (DT:[1058..1061] the) (JJ:[1062..1069] central)
                (NN:[1070..1076] enzyme))
            (PP (IN:[1077..1079] in)
              (NP
                (NP (DT:[1080..1083] the) (NN:[1084..1094] metabolism))
                (PP (IN:[1095..1097] of)
                  (NP (NNS:[1099..1110] xenobiotics)))))))))
    (,:[1110..1111] ,)
    (ADVP (RB:[1112..1116] thus))
    (VP (VBZ:[1117..1125] provides)
      (NP
        (NP (DT:[1126..1129] the) (NN:[1130..1135] focus))
        (PP (IN:[1136..1139] for)
          (NP
            (NP (NN:[1140..1153] consideration))
            (PP (IN:[1154..1156] of)
              (NP (NN:[1157..1177] methylenedioxyphenyl)
                  (NNS:[1179..1189] synergists)))
            (PP (IN:[1190..1192] as)
              (NP (JJ:[1193..1202] potential) (NNS:[1203..1210] hazards)))))))
    (.:[1210..1211] .)))

;section 10 Span:1215..1233
;Publication Types:
(SEC
  (FRAG (NNP:[1215..1226] Publication) (NNP:[1227..1232] Types)
        (::[1232..1233] :)))

;section 11 Span:1239..1245
;Review
(SEC
  (FRAG (NNP:[1239..1245] Review)))

;section 12 Span:1249..1292
;PMID: 789067 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1249..1253] PMID) (::[1253..1254] :) (CD:[1255..1261] 789067)
        (NN:[1262..1263] -LSB-) (NNP:[1263..1269] PubMed) (::[1270..1271] -)
        (NN:[1272..1279] indexed) (IN:[1280..1283] for)
        (NNP:[1284..1292] MEDLINE-RSB-)))
